03236nas a2200349 4500000000100000008004100001260004300042653001900085653002300104653002000127653001900147653002900166653001000195653002300205653003200228653002700260653002000287653002400307653003200331653002400363653001400387653002500401653002800426100001500454700001300469700001400482245009900496856010100595490000700696520216900703022001402872 2026 d c10/2026bOxford University Press (OUP)10aChagas disease10aCost effectiveness10aChronic Disease10aDecision Trees10aInternship and Residency10aItaly10aPrimary healthcare10aQuality-Adjusted Life Years10apublic health medicine10aHealth outcomes10aHealth care systems10aCost-effectiveness analysis10amedical residencies10aCommunity10aSensitivity analysis10aTreatment effectiveness1 aMarraffa P1 aMarega L1 aGianino M00aCost-effective but underused: evaluating screening strategies for indeterminate Chagas disease uhttps://academic.oup.com/eurpub/article-pdf/36/Supplement_5/ckag169.394/72463033/ckag169.394.pdf0 v363 a
Background
Chagas disease is a burdensome condition in non-endemic countries, yet underdiagnosed and underestimated. We aimed to assess cost-effectiveness of alternative screening models in Latin American residents in Italy.
Methods
A decision-analytic model combining a decision tree and a Markov model (annual cycles) was developed to simulate the lifetime progression of chronic disease. Four strategies were compared: usual care (no systematic screening), community-based active screening and two primary care–based approaches (standard and enhanced). Outcomes included costs, quality-adjusted life years (QALYs), incremental cost-effectiveness ratios (ICERs) and net monetary benefit (NMB), from a healthcare system perspective, using a €30,000/QALY threshold. Deterministic and probabilistic sensitivity analyses assessed robustness.
Results
Preliminary results estimated that all screening strategies were cost-effective compared with usual care, with ICERs below the threshold. In the base-case analysis, ICERs were €8,397/QALY for active screening, €14,249/QALY for standard primary care and €7,360/QALY for enhanced primary care. Per 10,000 individuals, active screening generated the largest health gains (+101 QALYs) even if with higher incremental costs (€850,478). Deterministic sensitivity analysis was primarily driven by disease prevalence and treatment effectiveness, probabilistic analysis confirmed robustness, with mean ICERs of €24,140/QALY (active screening) and €21,551/QALY (enhanced primary care) and probabilities of cost-effectiveness of 89.1% and 90.1%, respectively.
Conclusions
The lack of systematic screening for Chagas disease in migrants is a missed opportunity to improve health outcomes and resource use. Community-based approaches maximise health gains, while strengthened primary care offers a resource-efficient and scalable option. These findings support the integration of Chagas screening into routine public health and primary care services in Europe.
a1464-360X